Cargando…
Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma
BACKGROUND: Natural killer (NK) cells have been known to contribute to surveillance and control of hepatocellular carcinoma (HCC). However, the association of NK cell activity with stage and recurrence risk of HCC have not been fully evaluated. METHODS: Untreated patients with newly diagnosed HCC we...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199695/ https://www.ncbi.nlm.nih.gov/pubmed/34118869 http://dx.doi.org/10.1186/s12876-021-01833-2 |
_version_ | 1783707437547651072 |
---|---|
author | Lee, Han Ah Goh, Hyun Gil Lee, Young-Sun Jung, Young Kul Kim, Ji Hoon Yim, Hyung Joon Lee, Min-Goo An, Hyunggin Jeen, Yoon Tae Yeon, Jong Eun Byun, Kwan Soo Seo, Yeon Seok |
author_facet | Lee, Han Ah Goh, Hyun Gil Lee, Young-Sun Jung, Young Kul Kim, Ji Hoon Yim, Hyung Joon Lee, Min-Goo An, Hyunggin Jeen, Yoon Tae Yeon, Jong Eun Byun, Kwan Soo Seo, Yeon Seok |
author_sort | Lee, Han Ah |
collection | PubMed |
description | BACKGROUND: Natural killer (NK) cells have been known to contribute to surveillance and control of hepatocellular carcinoma (HCC). However, the association of NK cell activity with stage and recurrence risk of HCC have not been fully evaluated. METHODS: Untreated patients with newly diagnosed HCC were prospectively enrolled. Peripheral blood mononuclear cells were isolated at the time of diagnosis. Patients who had undergone surgery or radiofrequency ablation were classified as the curative treatment group, and their blood samples were collected again at 1 month after treatment. RESULTS: A total of 80 patients with HCC were enrolled. The mean age was 62.5 years. At baseline, interferon (IFN)-γ producing NK cell proportion was significantly lower in patients with Barcelona clinic liver cancer (BCLC) stage B, C, or D than in those with BCLC stage 0 (42.9% vs. 56.8%, P = 0.045). Among all patients, 56 patients had undergone curative treatment, and 42 patients re-visited at 1 month after curative treatment. There was no significant change in total NK cell and IFN-γ producing NK cell proportion from baseline to 1 month after treatment (all P > 0.05). During a median follow-up of 12.4 months, HCC recurred in 14 patients (33.3%). When patients were classified according to the IFN-γ producing NK cell proportion (group 1, ≥ 45%; and group 2, < 45%), HCC recurrence rate did not differ according to the IFN-γ producing NK cell proportion at baseline (log-rank test, P = 0.835). However, patients with < 45% IFN-γ producing NK cell proportion at 1 month after treatment had a significantly higher HCC recurrence rate than patients with that of ≥ 45% (log-rank test, P < 0.001). Multivariate analysis revealed that BCLC stage B (hazard ratio [HR] = 3.412, P = 0.045) and < 45% IFN-γ producing NK cell proportion at 1 month after treatment (HR = 6.934, P = 0.001) independently predicted an increased risk of HCC recurrence. CONCLUSIONS: Decreased NK cell activity is significantly associated with the advanced stage of HCC, and the increased recurrence risk of HCC after curative treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-021-01833-2. |
format | Online Article Text |
id | pubmed-8199695 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-81996952021-06-15 Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma Lee, Han Ah Goh, Hyun Gil Lee, Young-Sun Jung, Young Kul Kim, Ji Hoon Yim, Hyung Joon Lee, Min-Goo An, Hyunggin Jeen, Yoon Tae Yeon, Jong Eun Byun, Kwan Soo Seo, Yeon Seok BMC Gastroenterol Research BACKGROUND: Natural killer (NK) cells have been known to contribute to surveillance and control of hepatocellular carcinoma (HCC). However, the association of NK cell activity with stage and recurrence risk of HCC have not been fully evaluated. METHODS: Untreated patients with newly diagnosed HCC were prospectively enrolled. Peripheral blood mononuclear cells were isolated at the time of diagnosis. Patients who had undergone surgery or radiofrequency ablation were classified as the curative treatment group, and their blood samples were collected again at 1 month after treatment. RESULTS: A total of 80 patients with HCC were enrolled. The mean age was 62.5 years. At baseline, interferon (IFN)-γ producing NK cell proportion was significantly lower in patients with Barcelona clinic liver cancer (BCLC) stage B, C, or D than in those with BCLC stage 0 (42.9% vs. 56.8%, P = 0.045). Among all patients, 56 patients had undergone curative treatment, and 42 patients re-visited at 1 month after curative treatment. There was no significant change in total NK cell and IFN-γ producing NK cell proportion from baseline to 1 month after treatment (all P > 0.05). During a median follow-up of 12.4 months, HCC recurred in 14 patients (33.3%). When patients were classified according to the IFN-γ producing NK cell proportion (group 1, ≥ 45%; and group 2, < 45%), HCC recurrence rate did not differ according to the IFN-γ producing NK cell proportion at baseline (log-rank test, P = 0.835). However, patients with < 45% IFN-γ producing NK cell proportion at 1 month after treatment had a significantly higher HCC recurrence rate than patients with that of ≥ 45% (log-rank test, P < 0.001). Multivariate analysis revealed that BCLC stage B (hazard ratio [HR] = 3.412, P = 0.045) and < 45% IFN-γ producing NK cell proportion at 1 month after treatment (HR = 6.934, P = 0.001) independently predicted an increased risk of HCC recurrence. CONCLUSIONS: Decreased NK cell activity is significantly associated with the advanced stage of HCC, and the increased recurrence risk of HCC after curative treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-021-01833-2. BioMed Central 2021-06-12 /pmc/articles/PMC8199695/ /pubmed/34118869 http://dx.doi.org/10.1186/s12876-021-01833-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Lee, Han Ah Goh, Hyun Gil Lee, Young-Sun Jung, Young Kul Kim, Ji Hoon Yim, Hyung Joon Lee, Min-Goo An, Hyunggin Jeen, Yoon Tae Yeon, Jong Eun Byun, Kwan Soo Seo, Yeon Seok Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma |
title | Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma |
title_full | Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma |
title_fullStr | Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma |
title_full_unstemmed | Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma |
title_short | Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma |
title_sort | natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199695/ https://www.ncbi.nlm.nih.gov/pubmed/34118869 http://dx.doi.org/10.1186/s12876-021-01833-2 |
work_keys_str_mv | AT leehanah naturalkillercellactivityisariskfactorfortherecurrenceriskaftercurativetreatmentofhepatocellularcarcinoma AT gohhyungil naturalkillercellactivityisariskfactorfortherecurrenceriskaftercurativetreatmentofhepatocellularcarcinoma AT leeyoungsun naturalkillercellactivityisariskfactorfortherecurrenceriskaftercurativetreatmentofhepatocellularcarcinoma AT jungyoungkul naturalkillercellactivityisariskfactorfortherecurrenceriskaftercurativetreatmentofhepatocellularcarcinoma AT kimjihoon naturalkillercellactivityisariskfactorfortherecurrenceriskaftercurativetreatmentofhepatocellularcarcinoma AT yimhyungjoon naturalkillercellactivityisariskfactorfortherecurrenceriskaftercurativetreatmentofhepatocellularcarcinoma AT leemingoo naturalkillercellactivityisariskfactorfortherecurrenceriskaftercurativetreatmentofhepatocellularcarcinoma AT anhyunggin naturalkillercellactivityisariskfactorfortherecurrenceriskaftercurativetreatmentofhepatocellularcarcinoma AT jeenyoontae naturalkillercellactivityisariskfactorfortherecurrenceriskaftercurativetreatmentofhepatocellularcarcinoma AT yeonjongeun naturalkillercellactivityisariskfactorfortherecurrenceriskaftercurativetreatmentofhepatocellularcarcinoma AT byunkwansoo naturalkillercellactivityisariskfactorfortherecurrenceriskaftercurativetreatmentofhepatocellularcarcinoma AT seoyeonseok naturalkillercellactivityisariskfactorfortherecurrenceriskaftercurativetreatmentofhepatocellularcarcinoma |